Table 3

Selected ongoing studies using vaccines, antibody-drug conjugates, or engineered T-cell therapies in the treatment of cervical cancer

NCT identifierTitlePhasePlanned enrollmentPrimary endpoint(s)
NCT04697628Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)III482Overall survival
NCT04646005Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First-Line ChemotherapyII103Objective response rate
NCT04580771A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3–IVA Cervical Cancer, the IMMUNOCERV TrialII35Grade 3+ acute toxicity
NCT04405349Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical CancerII50Adverse events, overall response rate
NCT03444376The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical CancerI/II60Overall response rate
NCT02858310E7 TCR T Cells for Human Papillomavirus-Associated CancersI/II180Overall response rate
NCT03260023Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersI/II150Overall response rate and progression-free survival
NCT02379520HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)I32Dose-limiting toxicity
NCT02172911A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerI10Adverse effects
NCT03578406HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical CancerI20Maximum tolerated dose